These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 29095667)

  • 1. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes.
    Hess CN; Low Wang CC; Hiatt WR
    Annu Rev Med; 2018 Jan; 69():133-145. PubMed ID: 29095667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
    Pokrywka GS
    Postgrad Med; 2018 Apr; 130(3):287-298. PubMed ID: 29411675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
    Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 in cholesterol metabolism: from bench to bedside.
    Reiss AB; Shah N; Muhieddine D; Zhen J; Yudkevich J; Kasselman LJ; DeLeon J
    Clin Sci (Lond); 2018 Jun; 132(11):1135-1153. PubMed ID: 29895529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein cholesterol lowering treatment: the current approach.
    Crismaru I; Pantea Stoian A; Bratu OG; Gaman MA; Stanescu AMA; Bacalbasa N; Diaconu CC
    Lipids Health Dis; 2020 May; 19(1):85. PubMed ID: 32375792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of PCSK9 by nutraceuticals.
    Momtazi AA; Banach M; Pirro M; Katsiki N; Sahebkar A
    Pharmacol Res; 2017 Jun; 120():157-169. PubMed ID: 28363723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
    Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS
    Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PCSK9 in lipid metabolism and atherosclerosis.
    Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
    Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys.
    Vroom MM; Lu H; Lewis M; Thibodeaux BA; Brooks JK; Longo MS; Ramos MM; Sahni J; Wiggins J; Boyd JD; Wang S; Ding S; Hellerstein M; Ryan V; Powchik P; Dodart JC
    J Lipid Res; 2024 Feb; 65(2):100497. PubMed ID: 38216056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives.
    Fitzgerald G; Kiernan T
    Expert Rev Cardiovasc Ther; 2018 Aug; 16(8):567-578. PubMed ID: 29979908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Drugs for Lowering LDL-Cholesterol.
    Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.